Snapshot A 64-year-old female was brought to her primary care physician by her daughter due to poor appetite. When eliciting a history, you learn that the patient no longer finds joy in her hobbies, has feelings of worthlessness, is unable to sleep, and has issues concentrating. In addition to psychotherapy, the patient is prescribed sertraline. Introduction SSRIs are commonly considered first-line treatment for depression likely through increasing serotonergic activity usually takes 3-8 weeks for therpeutic effects to occur Treatment Drugs citalopram escitalopram fluoxetine fluvoxamine paroxetine sertraline Mechanism likely through decreasing the serotonin reuptake pump in presynaptic neurons this in turn increases synaptic serotonin availability and serotonin receptor occupancy in postsynaptic neurons serotonin reuptake receptor selectivity → relatively benign side-effects cytochrome P450 inhibitor citalopram and escitalopram are the SSRI of choice if you're concerned about drug-to-drug interactions Clinical use major depressive disorder (MDD, first-line treatment) obsessive-compulsive disorder post traumatic stress disorder panic disorder generalized anxiety disorder bulimia nervosa binge eating disorder social phobias hoarding disorder Toxicity much milder than other depression therapies weight gain fluoxetine has lowest risk can cause QTc prolongation anxiety, agitation, and insomnia GI distress sexual dysfunction (anorgasmia) can use alternative antidepressants such as bupropion and mirtazapine serotonin syndrome anxiety, restlessness, disorientation, autonomic manifestations (i.e., diaphoresis, hyperthermia, hypertension), and neuromuscular hyperactivity (i.e., myoclonus, hyperreflexia, muscle rigidity, tremor) SSRI discontinuation syndrome with abrupt discontinuation of the medication fluoxetine is less likely to cause symptoms post abrupt discontinuation
QUESTIONS 1 of 2 1 2 Previous Next Lab Values Blood Hematologic Cerebrospinal Sweat, Urine, and BMI Blood, Plasma, Serum Reference Range ALT 8-20 U/L Amylase, serum 25-125 U/L AST 8-20 U/L Bilirubin, serum (adult) Total // Direct 0.1-1.0 mg/dL // 0.0-0.3 mg/dL Calcium, serum (Ca2+) 8.4-10.2 mg/dL Cholesterol, serum Rec: < 200 mg/dL Cortisol, serum 0800 h: 5-23 μg/dL //1600 h: 3-15 μg/dL 2000 h: ≤ 50% of 0800 h Creatine kinase, serum Male: 25-90 U/LFemale: 10-70 U/L Creatinine, serum 0.6-1.2 mg/dL Electrolytes, serum Sodium (Na+) 136-145 mEq/L Chloride (Cl-) 95-105 mEq/L Potassium (K+) 3.5-5.0 mEq/L Bicarbonate (HCO3-) 22-28 mEq/L Magnesium (Mg2+) 1.5-2.0 mEq/L Estriol, total, serum (in pregnancy) 24-28 wks // 32-36 wks 30-170 ng/mL // 60-280 ng/mL 28-32 wk // 36-40 wks 40-220 ng/mL // 80-350 ng/mL Ferritin, serum Male: 15-200 ng/mLFemale: 12-150 ng/mL Follicle-stimulating hormone, serum/plasma Male: 4-25 mIU/mL Female: premenopause: 4-30 mIU/mL midcycle peak: 10-90 mIU/mL postmenopause: 40-250 pH 7.35-7.45 PCO2 33-45 mmHg PO2 75-105 mmHg Glucose, serum Fasting: 70-110 mg/dL2-h postprandial:<120 mg/dL Growth hormone - arginine stimulation Fasting: <5 ng/mLProvocative stimuli: > 7ng/mL Immunoglobulins, serum IgA 76-390 mg/dL IgE 0-380 IU/mL IgG 650-1500 mg/dL IgM 40-345 mg/dL Iron 50-170 μg/dL Lactate dehydrogenase, serum 45-90 U/L Luteinizing hormone, serum/plasma Male: 6-23 mIU/mL Female: follicular phase: 5-30 mIU/mL midcycle: 75-150 mIU/mL postmenopause 30-200 mIU/mL Osmolality, serum 275-295 mOsmol/kd H2O Parathyroid hormone, serume, N-terminal 230-630 pg/mL Phosphatase (alkaline), serum (p-NPP at 30° C) 20-70 U/L Phosphorus (inorganic), serum 3.0-4.5 mg/dL Prolactin, serum (hPRL) < 20 ng/mL Proteins, serum Total (recumbent) 6.0-7.8 g/dL Albumin 3.5-5.5 g/dL Globulin 2.3-3.5 g/dL Thyroid-stimulating hormone, serum or plasma .5-5.0 μU/mL Thyroidal iodine (123I) uptake 8%-30% of administered dose/24h Thyroxine (T4), serum 5-12 μg/dL Triglycerides, serum 35-160 mg/dL Triiodothyronine (T3), serum (RIA) 115-190 ng/dL Triiodothyronine (T3) resin uptake 25%-35% Urea nitrogen, serum 7-18 mg/dL Uric acid, serum 3.0-8.2 mg/dL Hematologic Reference Range Bleeding time 2-7 minutes Erythrocyte count Male: 4.3-5.9 million/mm3Female: 3.5-5.5 million mm3 Erythrocyte sedimentation rate (Westergren) Male: 0-15 mm/hFemale: 0-20 mm/h Hematocrit Male: 41%-53%Female: 36%-46% Hemoglobin A1c ≤ 6 % Hemoglobin, blood Male: 13.5-17.5 g/dLFemale: 12.0-16.0 g/dL Hemoglobin, plasma 1-4 mg/dL Leukocyte count and differential Leukocyte count 4,500-11,000/mm3 Segmented neutrophils 54%-62% Bands 3%-5% Eosinophils 1%-3% Basophils 0%-0.75% Lymphocytes 25%-33% Monocytes 3%-7% Mean corpuscular hemoglobin 25.4-34.6 pg/cell Mean corpuscular hemoglobin concentration 31%-36% Hb/cell Mean corpuscular volume 80-100 μm3 Partial thromboplastin time (activated) 25-40 seconds Platelet count 150,000-400,000/mm3 Prothrombin time 11-15 seconds Reticulocyte count 0.5%-1.5% of red cells Thrombin time < 2 seconds deviation from control Volume Plasma Male: 25-43 mL/kgFemale: 28-45 mL/kg Red cell Male: 20-36 mL/kgFemale: 19-31 mL/kg Cerebrospinal Fluid Reference Range Cell count 0-5/mm3 Chloride 118-132 mEq/L Gamma globulin 3%-12% total proteins Glucose 40-70 mg/dL Pressure 70-180 mm H2O Proteins, total < 40 mg/dL Sweat Reference Range Chloride 0-35 mmol/L Urine Calcium 100-300 mg/24 h Chloride Varies with intake Creatinine clearance Male: 97-137 mL/minFemale: 88-128 mL/min Estriol, total (in pregnancy) 30 wks 6-18 mg/24 h 35 wks 9-28 mg/24 h 40 wks 13-42 mg/24 h 17-Hydroxycorticosteroids Male: 3.0-10.0 mg/24 hFemale: 2.0-8.0 mg/24 h 17-Ketosteroids, total Male: 8-20 mg/24 hFemale: 6-15 mg/24 h Osmolality 50-1400 mOsmol/kg H2O Oxalate 8-40 μg/mL Potassium Varies with diet Proteins, total < 150 mg/24 h Sodium Varies with diet Uric acid Varies with diet Body Mass Index (BMI) Adult: 19-25 kg/m2 Calculator ( ) xy AC 7 8 9 ÷ 4 5 6 × 1 2 3 - 0 . = + Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK You have 100% on this question. Just skip this one for now. Take This Question Anyway (M2.PY.4867) A 25-year-old female is brought to the physician by her mother who is concerned about her recent behaviors. The mother states that her daughter has been collecting “useless items” in her apartment over the last year. When she tried to persuade her daughter to throw away several years’ worth of old newspapers, her daughter had an angry outburst and refused to speak to her for two weeks. The patient reluctantly admits that she keeps “most things just in case they become useful later on.” She also states that she has felt less interested in seeing friends because she does not want them to come over to her apartment. She has also not been sleeping well, as her bed has become an additional storage space and she must sleep on her futon instead. The patient states that she is sometimes bothered by the messiness of her apartment, but otherwise doesn't think anything is wrong with her behavior. Physical exam is unremarkable. Which of the following is the best next step in management? Review Topic QID: 109614 Type & Select Correct Answer 1 Cognitive behavioral therapy for obsessive-compulsive disorder 19% (11/57) 2 Admission to psychiatric facility 4% (2/57) 3 High dose SSRI for hoarding disorder 67% (38/57) 4 Tricyclic antidepressant for hoarding disorder 4% (2/57) 5 Intervention by patient’s mother to declutter the home 2% (1/57) M2 Select Answer to see Preferred Response SUBMIT RESPONSE 3